NLRP3 Inflammasome Blocking as a Potential Treatment of Central Insulin Resistance in Early-Stage Alzheimer's Disease.
Yulia K KomlevaIlia V PotapenkoOlga L LopatinaYana V GorinaAnatoly ChernykhElena D KhilazhevaAlla B SalminaAnton N ShuvaevPublished in: International journal of molecular sciences (2021)
We revealed that NLRP3 inflammasomes are required for insulin-dependent glucose transport in the brain and memory consolidation. Conclusions NLRP3 knockout protects mice against the development of BIR: Taken together, our data reveal the protective role of Nlrp3 deletion in the regulation of fear memory and the development of Aβ-induced insulin resistance, providing a novel target for the clinical treatment of this disorder.
Keyphrases
- nlrp inflammasome
- early stage
- insulin resistance
- type diabetes
- working memory
- blood pressure
- adipose tissue
- high fat diet induced
- single cell
- gene expression
- multiple sclerosis
- white matter
- electronic health record
- skeletal muscle
- blood glucose
- cognitive decline
- lymph node
- genome wide
- oxidative stress
- artificial intelligence
- polycystic ovary syndrome
- drug induced
- climate change
- mild cognitive impairment
- deep learning
- weight loss
- endothelial cells
- glycemic control
- neoadjuvant chemotherapy